Full Text View
Tabular View
No Study Results Posted
Related Studies
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
This study has been completed.
Study NCT00138086   Information provided by Groupe d'Etudes de Lymphomes de L'Adulte
First Received: August 29, 2005   Last Updated: September 6, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
B-Cell Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, B-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Zevalin plus BEAM
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Groupe d'Etudes de Lymphomes de L'Adulte


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services